Medtronic's Q3 Profit Falls 3% on a Trio of Costs

Medtronic's diabetes and surgical technologies growth takes a back seat to a bevy of additional quarterly costs that caused its adjusted profit to dip 3%.

Feb 18, 2014 at 12:25PM

The world's largest medical device company, Medtronic (NYSE:MDT), reported its third-quarter earnings results before the opening bell today. The report pointed to modest top-line expansion, as well as a number of higher expenses that actually caused its profit to dip.

Medtronic's quarterly revenue inched higher by 3.4% to $4.163 billion, from $4.027 billion in the year-ago period. International and emerging market sales provided the bulk of the spark, with international sales up 4% and emerging market revenue rising 12%, both on a constant currency basis.

Net income, however, fell 3% on an adjusted basis to $916 million as EPS dipped 2% to $0.91. Medtronic blamed the drop in EPS on three factors: nonrenewal of the U.S. research and development tax credit, higher Obamacare expenses as they relate to the medical device excise tax, and a large expense writedown related to its renal denervation in-process R&D following its HTN-3 trial not meeting its primary endpoint.

Of Medtronic's three operating segments, its diabetes group saw the most robust gains. Revenue rose 16% to $436 million due to the introduction of new products, including its artificial pancreas system, the MiniMed 530G. Unfortunately, this is by far Medtronic's smallest operating segment.

Growth in its more mature cardiac and vascular operation, as well as restorative therapies group, was more subdued.

Cardiac rhythm disease management revenue inched higher by 2% on a constant currency basis and accounted for close to 30% of total quarterly revenue at $1.184 billion. On the flip side in its cardiac and vascular segment, coronary revenue was flat excluding currency effects.

Restorative therapies delivered 5% sales growth excluding currency effects, with surgical technologies and neuromodulation revenue up 11% and 7%, respectively, while spine revenue remained flat at $744 million.

Looking ahead, Medtronic reaffirmed its prior guidance of 3%-4% revenue growth on a constant currency basis for the fourth quarter and full fiscal year, but tightened its full-year EPS range to $3.81-$3.83, from a range of $3.80-$3.85 issued in the prior quarter, implying adjusted EPS growth of 6% year over year. 


Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information